OmniAb licenses an antibody discovery platform to drug developers and academic institutions. OABI last reported earnings on Fri, Oct 30, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | Leerink Partners | Maintained | Buy | |
| Oct 7 | StoneX | Maintained | Buy | |
| Aug 17 | HC Wainwright & Co. | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in OABI in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OABI is in one of them and how their past OABI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OABI in an article yet. Here's the latest on the wider market.
About OmniAb
OmniAb is a discovery research company based in Emeryville, California. It licenses its antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses genetically engineered rats, mice and chickens whose immune systems produce fully human antibody candidates, which are then screened to find those suited to a partner's drug development. Customers use the resulting antibodies in their own therapy programs.
- Headquarters
- Emeryville, CA